DBV Technologies Shares Drop Nearly 5%, Falling Below €2.75

The Stock Breaks the €2.75 Support Again and Remains Below All Its Moving Averages

DBV Technologies stock has fallen by 4.82% to €2.73, dropping below the technical threshold of €2.75, which was previously breached at the end of June before a brief rebound. The stock is now trading 5.67% below its 20-day moving average (€2.89) and remains well below both the 50-day (€3.18) and 200-day (€3.08) moving averages, continuing the downward trend that began several weeks ago. The RSI at 43 remains neutral, with no marked overselling signal despite a nearly 19% decline over the past month. This session contrasts with the nearly 4% rebound recorded on Monday, June 29, which was insufficient to sustainably reclaim the 20-day moving average.

FDA Filing Schedule Pushed to Q3 2026 and Persistent Selling Pressure on Equity

The biotech company specified yesterday that the BLA filing for its Viaskin Peanut patch, intended for children aged 4 to 7 with peanut allergies, is now expected in the third quarter of 2026, after finalizing discussions with the Food and Drug Administration. The announcement had supported the stock on Monday, but today's session erases part of that gain, amid sustained selling positioning. According to reviewed statements, three funds hold a combined 3.45% of the capital in net short positions, up by 0.55 points over thirty days. This level, exceeding 3%, reflects ongoing skepticism about the stock, which should be monitored without drawing isolated conclusions. Over the past year, the stock has still gained nearly 77%, indicating a higher valuation base than at the start of its stock market journey in 2025. The €2.75 support remains the immediate technical marker to watch in the coming sessions.